Panel Discussion 1 George Williams Amgen. Barbara Tilley - Sample Size Estimation… Key point – considering both short term benefit of symptomatic treatment.

Slides:



Advertisements
Similar presentations
The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Lilly Yue, Ph.D.* CDRH, FDA,
Advertisements

Industry Issues: Dataset Preparation for Time to Event Analysis Davis Gates Schering Plough Research Institute.
Introduction to the unit and mixed methods approaches to research Kerry Hood.
EHR stakeholder workshop – 11th October EHR integration for clinical research: toward new interaction models ? Isabelle de Zegher.
Phase II/III Design: Case Study
Susan Boynton, VP, Global Regulatory Affairs, Shire
Comparator Selection in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.
Strengthening the Medical Device Clinical Trial Enterprise
Many Important Issues Covered Current status of ICH E5 and implementation in individual Asian countries Implementation at a regional level (EU) and practical.
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
Bayesian posterior predictive probability - what do interim analyses mean for decision making? Oscar Della Pasqua & Gijs Santen Clinical Pharmacology Modelling.
Statistical Issues in Incorporating and Testing Biomarkers in Phase III Clinical Trials FDA/Industry Workshop; September 29, 2006 Daniel Sargent, PhD Sumithra.
Clinical Significance
Elements of a clinical trial research protocol
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
Journal Club Alcohol and Health: Current Evidence May–June 2005.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2011.
Journal Club Alcohol and Health: Current Evidence March-April 2006.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Frank Mannino1 Richard Heiberger2 Valerii Fedorov1
Studying treatment of suicidal ideation & attempts: Designs, Statistical Analysis, and Methodological Considerations Jill M. Harkavy-Friedman, Ph.D.
Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.
EVAL 6970: Cost Analysis for Evaluation Dr. Chris L. S. Coryn Nick Saxton Fall 2014.
Copyright © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 4 EBM: A Historical Perspective.
New Role Models for the EDC Study Team Training, workflow and service provision DTI Conference Centre 1 st November 2005 Emma Banks Datatrial Limited.
Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.
Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School
Racial Differences in the Impact of HMO Coverage of Diabetes Blood Glucose Monitors on Self-Monitoring Connie A. Mah, M.S. Department of Ambulatory Care.
Participant Accrual. Numbers that Matter 3476= total number of women enrolled at least 95% retention at each visit, at each study site 100% attention.
Dissemination and Implementation Ellen Goldstein, MA, Kevin Grumbach, MD Translating Practice into Evidence: Community Engaged Research.
EHR Goal Setting and Impact on Quality of Care
The Intervention Program THE MISSING LINK IN BIOPHARMACEUTICAL SCIENCES TM.
Validation / citations. Validation u Expert review of model structure u Expert review of basic code implementation u Reproduce original inputs u Correctly.
Successful Concepts Study Rationale Literature Review Study Design Rationale for Intervention Eligibility Criteria Endpoint Measurement Tools.
CHAPTER 28 Translation of Evidence into Nursing Practice: Evidence, Clinical practice guidelines and Automated Implementation Tools.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
#1 Study Population. #2 What Is The Study Population? (1) Subset of the general population determined by the eligibility criteria GENERAL POPULATION eligibility.
The Role of CIS in Enabling Informed Decision Making Marion E. Morra, M.A. Montreal 2012.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
How to Start An Industry Sponsored Clinical Trial
Accountable Care: The Challenge of the Decade Michigan’s Premier Public Health Conference October 13, 2011 Kim Horn President and CEO Priority Health.
1 Chapter 6 SAMPLE SIZE ISSUES Ref: Lachin, Controlled Clinical Trials 2:93-113, 1981.
LifeCIT Development and pilot evaluation of a web-supported programme of Constraint Induced Therapy following stroke (LifeCIT) Meagher C 1, Conlon A 2,
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.
Dr. Sabine Brookman-May, MD, PhD Regional Therapeutic Area Expert Oncology (Europe, Middle East, Africa) - Janssen R&D Improving patients involvement in.
Clinical Trials for Comparative Effectiveness Research Mark Hlatky MD Mark Hlatky MD Stanford University January 10, 2012.
CLINICAL PROTOCOL DEVELOPMENT
FDA’s IDE Decisions and Communications
Presented by Rob Hemmings
Using Observation to Enhance Supervision CIMH Symposium Supervisor Track Oakland, California April 27, 2012.
Statistical Approaches to Support Device Innovation- FDA View
Donald E. Cutlip, MD Beth Israel Deaconess Medical Center
Randomized Trials: A Brief Overview
A Primer on Health Economics and Cost-Effectiveness
Aligning Estimands and Estimators – A Case Study Sept 13, 2018 Elena Polverejan Vladimir Dragalin Quantitative Sciences Janssen R&D, Johnson & Johnson.
A practical trial design for optimising treatment duration
S1316 analysis details Garnet Anderson Katie Arnold
Dose-finding designs incorporating toxicity data from multiple treatment cycles and continuous efficacy outcome Sumithra J. Mandrekar Mayo Clinic Invited.
Sue Todd Department of Mathematics and Statistics
Valerie Durkalski Medical University of South Carolina
Use of Real-World Data in Clinical Drug Development
Issues in Hypothesis Testing in the Context of Extrapolation
A New Approach to Clinical Trials
European Prevention Alzheimer’s Dementia
Patient-Centered Clinical Method
Use of Piecewise Weighted Log-Rank Test for Trials with Delayed Effect
Finding a Balance of Synergy and Flexibility in Master Protocols
Presentation transcript:

Panel Discussion 1 George Williams Amgen

Barbara Tilley - Sample Size Estimation… Key point – considering both short term benefit of symptomatic treatment and long term course of disease – statistical model Design challenge – choice of baseline – relative to course of disease (e.g. on state for Parkinson's disease, duration of symptomatic treatment, de novo patients, length of wash-out periods) -what question being addressed – short or long term effects Model – assume speed of initial symptomatic effect is identical across patients Questions Impact of subsequent other therapies Impact of subsequent on and off states in Parkinson example Arbitrary six month time interval in Parkinson example Importance of long term duration and relationship to dropouts/lost to follow-up

Chris Coffey - Adaptive Designs… Continuing challenges in the wide adoption of adaptive designs in clinical trials Recognize the wide variety of adaptive designs Statistical and logistical Quinlan et al (2010) Clinical Trials Technical – timely data capture, drug supply management, information flow Regulatory – perception/official positions Change management – comfort level with traditional approaches Importance of simulations of such designs – statistical properties of the design Challenges for industry as well – project plans must allow enough time to thoroughly do the necessary planning and conduct the simulations / scenario analyses

Xiaoxi Zhang - Prediction of Patient Accrual… Very important practical problem in the execution of clinical trials Realistic targets for sample size rather than sample size that cannot be achieved in time and on budget Aid in monitoring of accrual to take action to enhance accrual Sophisticated models for accrual prediction Incorporates uncertainty versus ad hoc approaches Recognize early projections will inherently have wide CIs

Xiaoxi Zhang - Prediction of Patient Accrual… Challenges include: Constancy of assumptions Varying start times by site – IRBs Seasonal variation/holidays Protocol changes – amendments Impact of external events – results of other trials, evolution of the science Recruitment strategies change during course of the trial Increasingly geographically disperse enrollment Models need to handle reality of multi-site trials and allow monitoring of accrual by site

Xiaoxi Zhang - Prediction of Patient Accrual… Importance of careful feasibility assessment Physicians typically overestimate ability to accrue Importance of retention Prediction of outcome events for event based trials Lag of reporting/impact of adjudication processes

Steve Kimmel and Andrea Troxel - Adherence… Importance of improving adherence In practice of medicine Low adherence can lead to underestimation of effects in clinical trials Lottery incentive has potential Impact of other covariates (e.g., age) Value of randomized trials to assess intervention Protocol design impact adherence Appropriate patient selection Protocol simplicity Importance of visit adherence as well Reduce missing data